Seeking Alpha·1d ago
Shoulder Innovations, Inc. (SI) Q3 2026 Earnings Call TranscriptShoulder Innovations, Inc. (SI) Q3 2026 Earnings Call Transcript
Shoulder Innovations appears to be executing an aggressive commercial scale-up, with quarterly revenue nearly doubling from $10.1 million in 2025Q1 to $17.2 million in 2026Q2 and gross margin expanding roughly 860 basis points to 78.3%, above the 67-70% posted by scaled spine peers such as Globus Medical and Alphatec.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.34+30.7% vs -$0.49 | $16M+4.9% vs $15M |
Q3 2026 Aug 6, 2026 | -$0.46-0.3% vs -$0.46 | $17M+3.7% vs $17M |
Q2 2026 May 13, 2026 | -$0.41+6.8% vs -$0.44 | $17M+14.9% vs $15M |
Q2 2026 Mar 10, 2026 | -$0.38+9.5% vs -$0.42 | $14M+12.7% vs $13M |
Shoulder Innovations, Inc. (SI) Q3 2026 Earnings Call Transcript
Shoulder Innovations, Inc. (SI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.48 per share a year ago.
52% Year-to-Date 2026 Revenue Growth GRAND RAPIDS, Mich., Nov. 5, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the third quarter ended September 30, 2026.
LOS ANGELES--(BUSINESS WIRE)-- #healthcareinnovation--COPE Health Solutions announced it has been selected as a finalist for QualTech, an industry event sponsored by the Centers for Medicare & Medicaid Services (CMS) through its Center for Clinical Standards and Quality (CCSQ). QualTech is designed to surface innovative technology solutions that address key healthcare quality priorities.CMS received more than 300 submissions across four QualTech opportunity areas and selected eight finalists. COPE Health Solutions.
Benchmark SI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Shoulder Innovations, Inc. (SI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.54 | $425.96M | -12.84 | 49.63% | -51.72% | -25.83% | — | |
| $71.05 | $9.58B | 17.33 | 16.65% | 17.76% | 11.82% | — | |
| $7.44 | $1.14B | -13.48 | 24.95% | -10.35% | -547.17% | — | |
| $0.29 | $40.59M | -3.64 | 14.21% | -10.17% | -23.45% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $105.59 | $20.43B | 26.33 | 7.2% | 8.96% | 6.05% | 0.91% |
Shoulder Innovations, Inc. (SI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Shoulder Innovations, Inc. (SI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 6, 2026·SEC
Jun 29, 2026·SEC
Mar 10, 2026·SEC
Get notified when SI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Shoulder Innovations, Inc. (SI) stock FAQ — growth, dividends, profitability & financials explained
Shoulder Innovations, Inc. (SI) reported $64.5M in revenue over the trailing twelve months. Revenue was $47.3M in fiscal year 2025. That is 145% more than the $19.3M of fiscal year 2023.
Shoulder Innovations, Inc. (SI) grew revenue by 54.9% over the trailing twelve months, compared with the twelve months before.
No. Shoulder Innovations, Inc. (SI) reported a net loss of $33.4M over the trailing twelve months.
Shoulder Innovations, Inc. (SI) had a return on equity (ROE) of -25.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Shoulder Innovations, Inc. (SI) had negative free cash flow of $42.7M over the trailing twelve months.
